Targeted Drug Approved for Acute Myeloid Leukemia with IDH1 Gene Mutations

The FDA has approved ivosidenib (Tibsovo) for the treatment of adults with acute myeloid leukemia (AML) that has a specific mutation in a gene called IDH1. Ivosidenib becomes the first FDA-approved IDH1-targeted treatment.

https://ift.tt/2nz0pMb